Outcomes of patients with systemic lupus erythematosus treated with belimumab: a post hoc efficacy analysis of five phase III clinical trials by British Isles Lupus Assessment Group-based Combined Lupus Assessment criteria
Objectives To determine belimumab efficacy assessed using the British Isles Lupus Assessment Group (BILAG)-based Combined Lupus Assessment (BICLA) in patients with systemic lupus erythematosus (SLE) from phase III belimumab randomised controlled trials (RCTs).Methods A post hoc analysis was carried...
Saved in:
| Main Authors: | Ronald F van Vollenhoven, Shereen Oon, Mandana Nikpour, Ioannis Parodis, Eric Morand, Adrian Levitsky, Julius Lindblom, Nurşen Çetrez, Leonardo Palazzo, Henri Ala |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2025-04-01
|
| Series: | RMD Open |
| Online Access: | https://rmdopen.bmj.com/content/11/2/e005444.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Response to Comment on “Effect of Belimumab on Preventing De Novo Renal Lupus Flares”
by: Ioannis Parodis, et al.
Published: (2024-10-01) -
Prospects for the use of belimumab in lupus nephritis
by: N. L. Kozlovskaya, et al.
Published: (2021-08-01) -
Clinical application of belimumab in lupus nephritis
by: Zhou Han, et al.
Published: (2022-10-01) -
EXPERIENCE WITH BELIMUMAB IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS
by: E. A. Aseeva, et al.
Published: (2015-09-01) -
Lupus clinical trial eligibility in a real-world setting: results from the British Isles Lupus Assessment Group-Biologics Register (BILAG-BR)
by: Ian N Bruce, et al.
Published: (2021-04-01)